Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $172.60 USD
Change Today -0.03 / -0.02%
Volume 1.0M
SLXP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (SLXP) Snapshot

Open
$172.72
Previous Close
$172.63
Day High
$172.76
Day Low
$172.60
52 Week High
09/24/14 - $172.98
52 Week Low
11/7/14 - $86.00
Market Cap
11.1B
Average Volume 10 Days
3.1M
EPS TTM
$-2.71
Shares Outstanding
64.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SALIX PHARMACEUTICALS LTD (SLXP)

salix pharmaceuticals ltd (SLXP) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (SLXP) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides Xifaxan tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; Apriso to maintain remission of ulcerative colitis (UC); Moviprep and Osmoprep for cleansing of the colon as a preparation for colonoscopy in adults; Relistor for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; Solesta to treat fecal incontinence; and Deflux to treat vesicoureteral reflux. It also offers Fulyzaq for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; Giazo, Colazal, and Uceris to treat mild to moderate UC; and Metozolv ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. The company’s products also comprise Ruconest to treat acute attacks in adult and adolescent patients with hereditary angioedema; Azasan azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; Anusol-HC and Proctocort for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Pepcid for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, it provides Diuril to treat hypertension and also as adjunctive therapy; Zegerid for the treatment of upper gastrointestinal conditions; Glumetza and Cycloset to enhance glycemic control in adults with type 2 diabetes mellitus; and Fenoglide to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. The company was founded in 1989 and is headquartered in Raleigh, North Carolina.

1,000 Employees
Last Reported Date: 03/2/15
Founded in 1989

salix pharmaceuticals ltd (SLXP) Top Compensated Officers

President of Medical, Research & Development ...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (SLXP) Key Developments

Salix Pharmaceuticals Ltd. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Salix Pharmaceuticals Ltd. reported consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net product revenues of $13,477,000 against $237,556,000 a year ago. Loss from operations was $423,442,000 against income from operations of $76,581,000 a year ago. Loss before income tax was $467,328,000 against income before income tax of $61,495,000 a year ago. Net loss was $287,645,000 or $4.51 per share basic and diluted against net income of $40,039,000 or $0.58 per share diluted a year ago. LBITDA was $138.0 million against EBITDA of $82.4 million a year ago. Non-GAAP net loss was $167.0 million or $2.61 per share diluted against non-GAAP net income of $48.3 million or $0.70 per share diluted a year ago. The decrease in net product revenues for the fourth quarter of 2014 was due to the company’s determination to substantially cease all sales efforts to wholesalers and sell only minimal amounts of its products during the quarter, as a result of the company’s previously-announced accelerated inventory reduction plan. For the year, the company reported net product revenues of $1,133,542,000 against $913,782,000 a year ago. Loss from operations was $490,097,000 against income from operations of $252,311,000 a year ago. Loss before income tax was $663,584,000 against income before income tax of $192,288,000 a year ago. Net loss was $414,911,000 or $6.53 per share basic and diluted against net income of $130,811,000 or $1.99 per share diluted a year ago. EBITDA was $315.0 million against $333.1 million a year ago. Non-GAAP net income was $142.0 million or $1.82 per share diluted against $197.8 million or $3.01 per share diluted a year ago.

Salix Pharmaceuticals Ltd., Q4 2014 Earnings Call, Mar 02, 2015

Salix Pharmaceuticals Ltd., Q4 2014 Earnings Call, Mar 02, 2015

Salix Pharmaceuticals Ltd. Announces Executive Changes

Salix Pharmaceuticals Ltd. announced that Carolyn J. Logan retired as President and Chief Executive Officer, and as a director on January 30, 2015. Effective upon Ms. Logan's retirement, the board of directors of the company has appointed Thomas W. D'Alonzo as Acting President and Chief Executive Officer and William C. Bertrand, Jr. as Acting Chief Operating Officer. Mr. D'Alonzo, 71, has served as a member of the Board since May 2000 and has been the Chairman of the Board since June 2010. Additionally, Mr. D'Alonzo joined the board of directors of BioDelivery Sciences International, in April 2014. From 2005 until 2012, Mr. D'Alonzo served on the board of directors of Amarillo Biosciences Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLXP:US $172.60 USD -0.03

SLXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $48.48 USD +2.21
Alkermes PLC $63.33 USD +0.39
Jazz Pharmaceuticals PLC $175.42 USD +2.03
Lupin Ltd 1,955 INR -18.15
Recordati SpA €16.68 EUR -0.62
View Industry Companies
 

Industry Analysis

SLXP

Industry Average

Valuation SLXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.7x
Price/Book 46.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.